Oric Pharmaceuticals, Inc. Jefferies Global Healthcare Conference in London - ORIC PHARMACEUTICALS INC
Explicit Guidance:
- Cash Runway: Company is well-capitalized with $345 million in cash and investments as of Q3 2024, providing a fully burdened runway extending into the second half of 2028. This runway covers the ongoing Himalayas 1 Phase III trial and the anticipated initiation of the Redwood 1 Phase III trial (Inozertinib).
- Trial Timing:
- Redwood 1 (Inozertinib Phase III): Intention to initiate in 2027.
- Himalayas 1 (Rinzimetastat Phase III): Started in July (referenced as "this year" in the text); study design is similar to Pfizer's 600-patient trial.
- Top-line Readout Expectations:
- Mevrotopone (Pfizer): Expected top-line results in Q1 of next year (implied Q1 2025/2026 depending on transcript context, but explicitly stated as "next year").
- Himalayas 1 (OREC): Previous assumption was top-line data in the first half of 2028.
Business-Segment Outlook:
- Rinzimetastat (Prostate Cancer):
- Post-Abiraterone Cohort: 10-month landmark PFS rates holding near 60%, comparable to Pfizer's data, with significantly reduced Grade 1 AEs (GI and hematologic toxicity) due to lower dose intensity (400mg vs Pfizer's 1.8g) and lack of CYP autoinduction.
- Post-AR Inhibitor Cohort: Data considered "inspiring" with 10-month landmark PFS at ~60%, contrasting sharply with the ~2 months expected for AR inhibitor monotherapy; durability remains strong with only 3 progressions out of 15 patients over a 5.5-month follow-up.
- Market Opportunity: Targeting ~17,000 patients in the post-abiraterone U.S. population ($3.5B market) and ~20,000 patients in the post-AR inhibitor U.S. population ($3.5B market). The "holy grail" expansion into castration-sensitive prostate cancer (CSBC) represents a potential $10 billion opportunity.
- Inozertinib (Lung Cancer):
- Target: EGFR atypical mutations and EGFR Exon 20 mutations.
- Performance: Demonstrated 84% overall response rate and 70% intracranial response rate in a heavily pre-treated cohort (2/3 with brain mets, 50% treatment-naïve for brain mets). Six-month landmark PFS rate of 88%.
- Differentiation: High CNS penetration is the key value proposition to prevent brain progression, a critical differentiator against competitors with toxicity profiles (liver, anemia, QTc) or lack of CNS activity.
- Rinzimetastat (Prostate Cancer):
Market and Competitive Outlook:
- Pfizer (Mevrotopone) Readout Impact:
- Big Miss Scenario: Considered statistically unlikely (<0% probability) given current data timelines.
- Near Miss Scenarios: Potential outcomes include a modest hazard ratio that lacks investor excitement or issues related to toxicity/dosing variability (food effect, CYP interactions) affecting Pfizer's control arm or treatment intensity.
- Read-Through: OREC expects limited negative read-through to Rinzimetastat due to superior safety profile (lower Cmax, no food effect, no CYP autoinduction) and different dosing regimen.
- J&J (HALDA/Riptac): Early PSA50/90 data is promising but durability and safety profiles (liver/kidney toxicity) remain unproven. OREC anticipates potential future combination strategies once the competitor is fully characterized, though mechanical incompatibility with AR inhibitors precludes immediate co-administration.
- Physician Choice Dynamics: Success will hinge on safety differentiation (similar efficacy but fewer toxicities), mirroring the adoption trajectory of Abilify (Apalutamide) and Darolutamide in the AR inhibitor space, where safety drove growth despite similar efficacy.
- Pfizer (Mevrotopone) Readout Impact:
Macro / Industry Outlook:
- Standard of Care Evolution: The industry consensus confirms "dogma" that CNS-penetrant drugs are essential in lung cancer to prevent early brain progression; this is a structural shift favoring Inozertinib.
- Trial Design Trends: Prostate cancer trials are increasingly powered for radiographic PFS as the primary endpoint with non-detrimental OS requirements, as seen in OREC's and Pfizer's Himalayas 1 designs.
- Control Arm Composition: Pfizer's MevPro1 control arm mix is shifting toward AR switches (enzalutamide) rather than chemotherapy, which may slightly lower the control arm's performance compared to historical expectations.
Strategic Initiatives:
- Rinzimetastat Expansion:
- Phase III Advancement: Proceeding with Himalayas 1 in post-abiraterone population (600 patients).
- Upfront Line Migration: If MevPro1 data confirms strong efficacy, management plans to accelerate Rinzimetastat into castration-sensitive prostate cancer (CSBC) settings to capture the larger market.
- Inozertinib Advancement:
- Phase III Initiation: Launching Redwood 1 (targeting EGFR atypicals) in 2027 without waiting for full Phase I durability readouts, driven by strong early signals.
- Operational Efficiency: Rinzimetastat dosing (400mg once daily with darolutamide) allows for lower exposure and better safety compared to Pfizer's high-dose fed regimen, reducing patient burden and potential compliance issues.
- Rinzimetastat Expansion:
Risks and Headwinds to Outlook:
- Pfizer Outcome Variability: A "near miss" by Pfizer (e.g., due to food-effect variability, high censoring, or dose reduction from toxicity) could delay or dampen enthusiasm for the PRC2 class, though OREC believes its specific pharmacokinetic profile mitigates this risk.
- Control Arm Imbalance: Pfizer's potential skew toward AR switches in the control arm could alter the perceived efficacy gap; OREC has capped the AR switch portion at 60% in its own protocol to prevent imbalance.
- Competitor Unknowns: J&J's Riptac program lacks durability and full safety data; potential toxicity or lack of long-term benefit could delay the anticipated shift to combination therapies.
- Regulatory/Operational: While not explicitly detailed, the reliance on Phase III success (Himalayas 1 and Redwood 1) for the full 2028 runway creates a binary execution risk if these trials face enrollment or data readout delays.
Management Tone on the Future:
- Confidence Level: High conviction. Management describes Rinzimetastat data as "remarkable" and the Inozertinib CNS profile as "phenomenal."
- Differentiation Focus: Strong emphasis on "safety as the differentiator" (lower toxicity, cleaner profile) rather than efficacy superiority, drawing parallels to the AR inhibitor market evolution.
- Strategic Agility: Willing to accelerate into earlier lines of therapy (CSBC) if the PRC2 mechanism is validated by Pfizer's data, signaling an aggressive growth mindset contingent on clinical readouts.
- Risk Mitigation: Proactively designed trials (e.g., control arm caps, specific dosing) to insulate OREC's data from potential pitfalls affecting competitors.
Miscellaneous:
- Company Mission: "Overcoming Resistance in Cancer" (OREC).
- Funding Status: Fully funded to second half of 2028; no immediate dilution risk anticipated based on current cash position.
- Clinical Trial Comparison: OREC's Phase III design (600 patients, 0.66 HR powered) is intentionally aligned with Pfizer's to allow direct side-by-side comparison upon readout.
- Company
- ORIC PHARMACEUTICALS INC
- Keywords
- ORIC PHARMACEUTICALS INC